Clinical Research Articles

We’ve curated the latest clinical research articles we think are worth reading.

Articles

Constructing Composites to Optimise Cognitive Outcomes

Article:
The relative insensitivity of traditional cognitive outcome measures to describe more subtle and selective cognitive impairment has resulted in a recent boon in cognitive composite measures.
This article is taken from the Journal of Clinical Studies, Volume 9, Issue 2, by Henry J. Riordan, Ph.D.

At the Forefront of Drug Discovery and Development: Small to Midsize Biotech/Biopharma Companies are the Leaders of Innovation

Article:
Today, the innovators of drug discovery and development are the smaller, biotech and biopharma companies around the world. According to a report from HBM Partners AG, in the past several years, more than 60% of new drugs approved originated at small and midsize companies – those outside the 30 largest pharmaceutical firms.
This article is taken from PharmaVoice, April 2017, by Peter Benton.

Exploring the Future of Clinical Research for Immune-Mediated Inflammatory Diseases

Article:
Significant and ongoing research into IMID pathology and genetic links have led to the knowledge that underpinning these diseases is the dysregulation of the immune system, which leads to widespread and chronic inflammation.

IT’S ALL ABOUT RELATIONSHIPS: The key to improving study site performance

Article:
In this latest PharmaTimes Magazine article, Jeff Zucker explains the key to improving study site performance.
This article is taken from Pharma Times Magazine, April 2017, by Jeff Zucker.

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

Article:
The first in a new class of gene-silencing drugs, known as inclisiran, has been shown to halve cholesterol levels in patients at risk of cardiovascular disease.
This article is taken from The New England Journal of Medicine, March 17, 2017, including quotes from Kausik K. Ray, M.D., Ulf Landmesser, M.D., Lawrence A. Leiter, M.D., David Kallend, M.D., Robert Dufour, M.D., Mahir Karakas, M.D., Tim Hall, M.D., Roland P.T. Troquay, M.D., Traci Turner, M.D., Frank L.J. Visseren, M.D., Peter Wijngaard, Ph.D., R. Scott Wright, M.D., and John J.P. Kastelein, M.D., Ph.D.

Rare Disease Research: Q&A with Dr. Murphy on the Current State of R&D Activity in Orphan Disease Trials

Article:
Rare Disease Research: Q&A with Dr. Murphy on the Current State of R&D Activity in Orphan Disease Trials.
This article is taken from Pharmafocus, March 2017, by Michael Murphy, M.D., Ph.D.

Rare Disease Day Turns Spotlight on Research

Article:
The international 10th annual Rare Disease Day, which is coordinated by the European Organization for Rare Diseases, seeks to help the public understand how rare diseases impact people’s lives, and bring these diseases to the attention of policy makers, public authorities, industry representatives, researchers, and health professionals.
This article is taken from PharmaVoice, February 2017, by Kim Ribbink, including quotes from Michael Murphy.

Refining Clinical Diagnosis of Progressive Supranuclear Palsy: Implications for Disease Modification Trials

Article:
The manifold symptoms and broad phenotypic variability of PSP may in part account for its diagnostic challenges, particularly in the early stages of the disease. This review will delineate various diagnostic schema in defining PSP with an overall aim of improving diagnostic accuracy in clinical trials, resulting in decreased patient heterogeneity with accompanying improvement of signal detection in the assessment of putative therapeutic agents.
This article is taken from The Journal for Clinical Studies, Volume 9, Issue 1.

Maximizing Patient Recruitment in Rare Disease Research

Article:
This article discusses the steps that researchers can take, particularly when it comes to patient recruitment. This article was written by Jeffrey Zucker, Vice President, Feasibility and Recruitment Optimization at Worldwide Clinical Trials and Barbara Zupancic, Director of Global Patient Recruitment and Retention at Worldwide Clinical Trials.
This article is taken from PharmaVoice, February 2017, by Jeffrey Zucker and Barbara Zupancic.

The Rise of Registries

Article:
Identifying risk has consistently remained a top priority in clinical trials – especially in transformative therapies. With changes to study development, safety, value and innovation, the widespread utilisation of registries could mean a transformational shift across the whole trial landscape.
This article is taken from the European Biopharmaceutical Review, January 2017, by Dr. Paola Antonini, Lorna Graham, and Dr. Michael Murphy.

Worldwide Clinical Trials Named “Best in Neuroscience Therapeutics” by Corporate LiveWire Healthcare & Life Sciences Awards 2016

Article:
Corporate LiveWire recognized Worldwide Clinical Trials as “Best in Neuroscience Therapeutics” in its special issue announcing the winner of its 2016 Healthcare & Life Sciences Awards, where this company profile was featured. The awards celebrate the most innovative and successful projects carried out around the world over the previous 12 months.
This article is by Peter Benton, discussing the Corporate LiveWire recognition.

Sex Differences in the Psychopharmacological Treatment of Depression

Article:
This article reviews the history and current research on sex effects of antidepressant treatments.
This article is taken from the Dialogues in Clinical Neuroscience, Volume 18, Issue 4, 2016, by John J. Sramek, Michael F. Murphy, MD, PhD, and Neal R. Cutler, MD.

Managing Benefits and Risks of Opioids in Paediatric Populations: A Review of FDA Paediatric Advisory Committee on Opioid Studies

Article:
The FDA recently conveyed a meeting to discuss opioid use in the paediatric populations with the purpose of ensuring a balance between the exuberance to control the spread of opioid use disorders whilst a guaranteeing that patients continue to have access to the appropriate treatments for their pain and, importantly, to address ways to incorporate paediatric populations into future clinical studies of opioids.
This article was published in the International Pharmaceutical Industry Journal, Volume 8, Issue 4, by Barry J. Dussault and Henry J. Riordan.

Why We Need to Redefine The “Team” in Rare Disease Trials

Article:
Dr. David Frakes M.D., senior vice president of Project Management for Neuroscience at Worldwide Clinical Trials, discusses why we need to redefine the “team” in rare disease trials.
This article is taken from The CenterWatch Monthly, Volume 23, Issue 12, by Dr. David Frakes.

Hypothesis Generation: An Essential Component of Informed Healthcare Management

Article:
In this article, Michael F. Murphy, Chief Medical and Scientific Officer at Worldwide Clinical Trials, concludes that although the applicability of the TCoC estimator in population healthcare management and in program development is intuitive, applications are apparent for other stakeholders given its accessibility and variety of model inputs, accentuating the importance of hypothesis generation as well as testing for therapeutic optimization on a population level.
This article is taken from American Health & Drug Benefits, Volume 9, Issue 9, December 2016, by Thanh-Nghia Nguyen, DrPH, MPH, MBA; Jeffrey Trocio, MPH; Stacey Kowal, MS; Cheryl P. Ferrufino; Julie Munakata, MS; and Dell South, PharmD.

Patient Characteristics, Adherence, and a Metric of Organizational Performance in Behavioral Health

Article:
Michael F. Murphy, Chief Medical and Scientific Officer at Worldwide Clinical Trials, states that factors related to medication adherence and cost suggest that antipsychotic medication use can improve outcomes in selected patients.
This article is taken from American Health & Drug Benefits, Volume 9, Issue 7, October 2016, by Marie-Hélène Lafeuille, MA; Christian Frois, PhD; Michel Cloutier, PhD; Mei Sheng Duh, MPH, ScD; and Patrick Lefebvre, MA; Jacqueline Pesa, PhD, MPH; Zoe Clancy, PharmD; John Fastenau, RPh, MPH; and Mike Durkin, MSc.

21st Century Cures Act Holds Promise for Patients

Article:
The 21st Century Cure Act promises to promote the development and hasten the approval of new drugs and devices, especially treatments for cancer and rare diseases. Michael Murphy, Chief Medical and Scientific Officer at Worldwide Clinical Trials, discusses the opportunities within patient-focused drug development and disease-related biomarkers.
This article is taken from PharmaVoice, November/December 2015, with quotes from Michael Murphy.

The Changing Clinical Landscape

Article:
As clinical operations and development have become increasingly complex—from protocols to new science—sponsors, CROs, and sites need to manage a multitude of variables to meet the growing demand for new treatments. Michael Murphy, Chief Medical and Scientific Officer at Worldwide Clinical Trials, states that “the opportunity lies with a participatory approach that leverages the patient perspective in the research experience to inform protocol design and the burden of proposed assessments.”
This article is taken from PharmaVoice, June 2016, by Denise Myshko and Taren Grom, with quotes from Michael Murphy.

Going All In on eCOA

Article:
Significant growth opportunities in the eCOA field mean the industry is calling out for solutions, advice and guidance that can help deliver on its promises.
This article is taken from The Journal for Clinical Studies, Volume 8, Issue 6, with quotes by Jeffrey Zucker.

Key Considerations for ‘Siteless’ Clinical Trials

Article:
Advancements in technology are impacting many aspects of clinical research, opening doors to innovative study designs and clinical operations that may not have been possible even five years ago.
This article is taken from The Journal for Clinical Studies, Volume 8, Issue 6, by Michael Murphy.

Improving Screen Failure and Recruitment Rates in Alzheimer’s Disease Clinical Trials

Article:
The failures of clinical trials in Alzheimer’s Disease (AD) have been attributed to a variety of factors, including an inadequate understanding of mechanisms of action and/or poor target engagement; however, other factors such as inadequate study design, wrong clinical stage of AD matched to the drug’s mechanism of action, limited statistical power of endpoint measures, and inclusion of participants who may otherwise not be eligible for the trial, have all contributed to the poor success rate of AD trials.
This article is taken from the Journal for Clinical Studies, Volume 8, Issue 5, Pg 40 and is authored by Henry J. Riordan, Ph.D.

Improving Development of Antiepileptic Drugs for Rare Forms of Epilepsy

Article:
Therapeutic development in rare diseases involves many challenges such as an incomplete understanding of the disease to inform trial design, requirements for new or more sensitive and specific outcome measures, and difficulties of recruiting a small sample to participation, among others.
This article is taken from the Journal for Clinical Studies, Volume 8, Issue 3, Pg 34 and is authored by Idil Çavuş, M.D. PhD.

Electronic Data Acquisition: Q&A with Dr. Michael Murphy

Article:
Dr. Michael Murphy at Worldwide Clinical Trials tackles the big questions on the minds of drug development and clinical research professionals, and explores the impact of technology on today’s studies.
This article is taken from International Clinical Trials August 2016, by Dr. Michael F. Murphy, pages 51-54. © Samedan Ltd.

A Review of FDA’s Action Plan to Proactively Reduce Prescription Opioid Abuse

Article:
The increasing rates of opioid abuse and dependence, and the alarming rise in the number of prescription opioid-related overdoses and deaths in the US has caused government agencies around the globe to launch various initiatives in an attempt to stem the tide of this devastating public health crisis.
This article is taken from the Journal for Clinical Studies, April 15, 2016, by Henry J. Riordan, Ph.D.

Evolving Landscapes in Multiple Sclerosis Research: Adaptive Designs and Novel Endpoints

Article:
The increasing amount of highly effective treatment options in relapsing forms of multiple sclerosis (MS) requires innovative clinical trial design strategies. These strategies may encompass the application of adaptive designs as well as the adoption of innovative primary outcome measurements.
This article is taken from Multiple Sclerosis and Demeyelinating Disorders, April 1, 2016, by Manolo E. Beelke, Paola Antonini and Dr. Michael F. Murphy.

Sticking with Tradition: Clinical Trial Sites Prefer Paper Records

Article:
According to a recent survey, the majority of clinical trial site staff prefers paper-based assessments over eCOA solutions.
This article is taken from Outsourcing-pharma, March 9, 2016, by Melissa Fassbender.

Unified Approaches to Rare Disease Research

Article:
Rare Disease Day aims to increase awareness of rare diseases and their impact on patients, families, and medical professionals. Hundreds of organizations are helping doctors find diagnoses and sufferers find solace.
This article is taken from Clinical Informatics News, March 8, 2016, by Maxine Bookbinder.

Promises to Keep: Informing Healthcare Decisions through Cardiovascular Outcomes Studies

Article:
Despite the global burden of cardiovascular disease, investment in cardiovascular drug development has stagnated over the past two decades, which is a relative underinvestment compared to other therapeutic areas.
This article is taken from PharmaVoice, February 2016, by Dr. Michael F. Murphy, MD, PhD and Paola Antonini, MD, PhD.

Updated Diagnostic Criteria for Parkinson’s Disease: Implications for Clinical Trials

Article:
To update the criteria to diagnose Idiopathic Parkinson’s Disease’s (IPD), the Movement Disorders Society (MDS) has recently published Clinical Diagnostic Criteria for Parkinson’s disease (MDS-PD), designed specifically for use in clinical research, but also as a general guide to clinical diagnosis of IPD consequent to Lewy body pathology.
This article is taken from the Journal for Clinical Studies, February 24, 2016 by Tomislav Babic, MD, PhD.

Rare Diseases: Meeting the Unique Challenges of Orphan Drug Development

Article:
While individually rare, orphan diseases are actually collectively common, with an estimated 350 million sufferers worldwide. Creating a pharmaceutical development program for the treatment of a rare disease can, however, prove to be a monumental task.
This article is taken from Applied Clinical Trials, January 21, 2016, by Dr. Michael F. Murphy, MD, PhD.

Burn Trauma: An Emerging Model for Acute Pain

Article:
Emphasis in acute pain studies has shifted to outcomes that go beyond “good pain relief” to reductions in the risk of developing chronic pain, acute medical conditions, and the development of psychological disturbances due to pain.
This article is taken from the Journal for Clinical Studies, December 2015, by Jayne Abraham, PhD.

Optimizing the Design of Dementia with Lewy Bodies Trials

Article:
Dementia with Lewy bodies (DLB) is a neurodegenerative disorder characterised by parkinsonism and cognitive impairment but may also manifest multiple symptoms of dysautonomia, rapid eye movement (REM) sleep behavior disorders, hallucinations, and cognitive fluctuations.
This article is taken from the Journal for Clinical Studies, April 15, 2016, by Tomislav Babic, MD, PhD and Henry J. Riordan, PhD.

Key Design Considerations On Comparative Clinical Efficacy Studies For Biosimilars: Adalimumab as an Example

Article:
The global development of a biosimilar product is a methodologically complex affair, lined with potential design pitfalls and operational missteps to be avoided. Without careful attention to experimental design and meticulous execution, a development programme may fail to demonstrate equivalence, and not receive regulatory approval based on current guidance.
This article is taken from RMD Open, December 19, 2015, by Zhihong Lai and Anna La Noce.

Exploratory Biomarker Study of the Triple Reuptake Inhibitor SEP-432 Compared to the Dual Reuptake Inhibitor Duloxetine in Healthy Normal Subjects

Article:
SEP-432 is a triple monoamine reuptake inhibitor of norepinephrine (NE), serotonin (5-HT), and dopamine (DA), based on in vitro binding studies. Leaders sought evidence that SEP-432 engages these monoamine systems by measuring concentrations of monoamines and/or their main metabolites in cerebrospinal fluid (CSF) and plasma and comparing results to duloxetine, a dual reuptake inhibitor of NE and 5-HT.
This article is taken from CNS Neuroscience & Therapeutics, December 11, 2015, by John J. Sramek, Larry W. Hardy, Peter Bieck, Cynthia Zamora, Mark Versavel, Jahnavi Kharidia, Todd Grinnell, Yu-Luan Chen, Michael Sullivan, Hong Ding & Neal R. Cutler.

The 21st Century Cures Act

Article:
Thought leaders respond to the relevant ways the 21st Century Cures Act is going to impact the industry.
This article is taken from PharmaVoice, November/December 2015, by Matt Gross, Mike Hodgson, Ken Horne, Michael Murphy, MD, PhD.

A Teachable Moment in Health Benefits Design

Article:
In their article, Carlton and colleagues evaluate the expected costs and budget impact of interventional, short-term therapy for chronic venous disease from a third-party US payer perspective. Their budget impact model transcends the immediate clinical and budgetary implications for the treatment of varicose veins and provides a “teachable moment” for a process that is foundational to informed health benefits design.
This article is taken from American Health & Drug Benefits, August 9, 2015, by Dr. Michael F. Murphy, MD, PhD.

Evolution of Value for Oncology Therapies

Article:
The healthcare environment is a mosaic of stakeholders, each with remarkably different demands for data addressing product attributes. These often conflicting perspectives require access to a portfolio of interventional and observational research designs to effectively demonstrate the value of a novel oncology therapy in development.
This article is taken from Applied Clinical Trials, September 8, 2015, by Thomas F. Gross, Nicole Sweeney, and Dr. Michael F. Murphy, MD, PhD.

Minimising Placebo Response in Chronic Pain Trials

Article:
This brief review elucidates some of the factors that contribute to the heightened placebo response in trials of drugs for common chronic pain indications such as osteoarthritic pain, low back pain and neuropathic and highlights easily implemented maneuvers to remedy this problem.
This article is taken from the Journal for Clinical Studies,October 6, 2015, by Henry J. Riordan, PhD.

Optimising MRI in Multiple Sclerosis Drug Development

Article:
This review will summarize important design issues in proof of concept studies of RRMS with an emphasis on optimizing neuroimaging outcome measures designed to help speed clinical development of novel drugs and biologics.
This article is taken from the Journal for Clinical Studies, August 20, 2015, by Tomislav Babic, MD, PhD and Henry J. Riordan, PhD.

Methodological Issues in Design and Conduct of Opioid Use Disorders Studies

Article:
There are several unique methodological challenges in the design and conduct of studies assessing the efficacy of various opioid use disorder treatments. Nonetheless, with careful planning these can all be effectively managed.
This article is taken from the Journal for Clinical Studies, June 15, 2015, by Barry J. Dussault, Jr., MBA, Henry J. Riordan, PhD.

Demonstrating Value for Biosimilars: A Conceptual Framework

Article:
The objectives of this paper are to identify factors that facilitate and inhibit the development, commercialization, and adoption of biosimilars, and to recommend modifications in program design that are likely to support the demonstration of the value of biosimilars for payers, providers, and patients.
This article is taken from American Health & Drug Benefits, May 2015, by Sotiris Rompas, PhD; Thomas Goss, PharmD; Sally Amanuel, BSc, MA, MBA; Victoria Coutinho, BSc, PhD; Zhihong Lai, PhD; Paola Antonini, MD, PhD; Michael F. Murphy, MD, PhD.

CSF Biomarkers of Disease Modification in Alzheimer’s Disease

Article:
Although several CSF biomarkers have shown some degree of utility in diagnostic accuracy as biomarkers in predicting conversion to AD from mild cognitive impairment (MCI), and as a tool to enrich patients for clinical trials to increase statistical power, these biomarkers have not shown similar success in evaluating the effectiveness of therapeutic interventions in AD.
This article is taken from the Journal for Clinical Studies, May 14, 2015, by Henry J. Riordan, PhD, and Neal R. Cutler, MD.

Overcoming Regulatory Challenges in Cognitive Drug Development

Article:
This paper describe some of the more salient regulatory challenges involved in determining the appropriateness and legitimacy of a possible target involving cognitive impairment associated with various CNS – (central nervous system) disorders and how to overcome these challenges.
This article is taken from the Journal for Clinical Studies, February 9, 2015, by Henry J. Riordan, PhD.

CSF biomarker variability in the Alzheimer’s Association quality control program

Article:
The cerebrospinal fluid (CSF) biomarkers amyloid beta 1–42, total tau, and phosphorylated tau are used increasingly for Alzheimer’s disease (AD) research and patient management. However, there are large variations in biomarker measurements among and within laboratories.
This article is taken from Alzheimer’s & Dementia, The Journal of the Alzheimer’s Association by Niklas Mattssona, Ulf Andreasson, Staffan Persson, Maria C. Carrillo, Steven Collins, Sonia Chalbot, Neal Cutler, Diane Dufour-Rainfray, Anne M. Fagan, Niels H. H. Heegaard, Ging-Yuek Robin Hsiung, Bradley Hyman, Khalid Iqbal, et. al.

Chronic Respiratory Diseases and Risk Factors in 12 Regions of the Russian Federation

Article:
Estimation suggests that at least 4 million people die, annually, as a result of chronic respiratory disease (CRD). The Global Alliance against Chronic Respiratory Diseases (GARD) was formed following a mandate from the World Health Assembly to address this serious and growing health problem.
This article is taken from the International Journal of COPD, by Alexander G. Chuchalin, Nikolai Khaltaev, Nikolay .S Antonov, Dmitry .V Galkin, Leonid G. Manakov, Paola Antonini, Michael Murphy, Alexander .G Solodovnikov, Jean Bousquet, Marcelo H.S. Pereira, Irina V. Demko.

The Death of CNS Drug Development: Overstatement or Omen?

Article:
CNS drugs often start off in a relatively poorer position than drugs in other indications, not just because they are viewed as a having a relatively higher risk and lower priority, but also because CNS drug developers are not routinely taking advantage of the regulatory tools available to them, such as Priority Review and Fast Track designation.
This article is taken from the Journal for Clinical Studies, by Henry J. Riordan, PhD and Neal R. Cutler, MD.

Updated Diagnostic Criteria for Alzheimer’s Disease: Implications for Clinical Trials

Article:
This CNS watch will review new criteria, the role of biomarkers in the various stages of AD, the importance of early detection in emerging markets characterized by a predominance of undiagnosed cases, and the impact of these new criteria on drug development in terms of trial design, conduct, and subject selection in AD trials.
This article is taken from the Journal for Clinical Studies, by Henry J. Riordan PhD, and Erin B. Kornsey.

FDA’s New Risk Evaluation and Mitigation Strategy for Opioids

Article:
The current class-wide Risk Evaluation and Mitigation Strategy (REMS) constitutes the most far-reaching REMS to date with implications for practitioners, hospital staff, pharmacists, patients and analgesia drug developers.
This article is taken from the Journal for Clinical Studies, by Henry J. Riordan, PhD.

Complying with FDA Guidance on the Prospective Assessment of Suicidality in Clinical Trials

Article:
The purpose of this CNS Watch is to outline the essential elements involved in prospective suicide assessment in trials of drugs with central nervous system (CNS) effects.
This article is taken from the Journal for Clinical Studies, by Henry J Riordan, PhD.

The Role of Amyloid Biomarkers in Accelerating Alzheimer’s Disease Drug Development

Article:
This CNS watch will summarize opinions, as well as the utility of amyloid targeting drugs and biomarkers in AD drug development, including the possible use of amyloid-based surrogate biomarkers as primary efficacy variables to accelerate AD drug development.
This article is taken from the Journal for Clinical Studies, by Henry J. Riordan, PhD.

Postapproval Development Options in COPD: A Case Study in Value-Based Healthcare Systems

Article:
The introduction of novel therapeutics into an era of globaization mandates research programs that are relevant to the registration process, payers and purchasers, transparent pricing, and rule-driven business practices, while providing data relevant to marketing initiatives internationally.
This article is taken from American Health and Drug Benefits, by Dr. Michael F. Murphy, MD, PhD; Paola Antonini, MD, PhD; Zhihong Vicki Lai, PhD.

FDA’s New Guidance on Biomarker and Patient Reported Outcome Qualification

Article:
This brief review will summarize this guidance, outline the mechanism for ensuring DDT qualification, and suggest areas for further elucidation.
This article is taken from the Journal for Clinical Studies, by Henry J. Riordan, PhD.

The Impact of Decreased Bead Count to Determine MFI Values for Total-Tau, Amyloid Beta 1-42, and Phospho-Tau 181 in Human Cerebrospinal Fluid by Flow Based Fluorometric Immunoassay

Article:
Alzheimer’s disease is the leading cause of human dementia. The lack of diagnostic tests and limited therapeutic options has driven the search for endogenous biomarkers. The INNO-BIA AlzBio3 assay is a multiplex flow-based immunoassay measuring A42, tau, and p-tau in cerebrospinal fluid (CSF). This study assesses assays performance under varying bead count (BC) parameters.
This article is taken from the Journal of Pharmaceutical Companies, by Olaf Bjornstal, Kathryn Rogers, Wei Zhang, Richard Delhaye, Michele Malone, Steve Unger, William Nowatzke.

Improving Academic Leadership and Oversight in Large Industry-Sponsored Clinical Trials: the ARO-CRO Model

Article:
Although numerous models can be entertained, the ARO-CRO model is uniquely structured to meet the demand for greater assurance of integrity in clinical trials and the needs of each stakeholder in the process.
This article is taken from Blood by the American Society of Hematology by Neil A. Goldenberg, Alex C. Spyropoulos, Jonathan L. Halperin, Craig M. Kessler, Sam Schulman, Alexander G. G. Turpie, Allan M. Skene, Neal R. Cutler, and William R. Hiatt, for the Antithrombotic Trials Leadership and Steering Group.

The Impact of DSM-5 on Psychiatric Clinical Trials: Challenges and Opportunities

Article:
This brief review will summarize some of the more salient proposed criteria revisions, their implications for psychiatric trials, and resultant opportunities for psychiatric drug developers.
This article is taken from the Journal for Clinical Studies, by Henry J. Riordan, PhD

Innovative Designs for Chronic Pain Trials

Article:
This review highlights innovative trials designs that may improve signal detection for novel therapeutics in chronic pain with a predominantly proof of concept emphasis.
This article is taken from the Journal for Clinical Studies by Henry J. Riordan, PhD and Dr. Michael F. Murphy, MD, PhD.

See what Worldwide Clinical Trials can do for you.

Fill out the brief form below to get in touch.

Your form has been successfully submitted! Thank you for your interest in Worldwide Clinical Trials. We will respond to your inquiry as soon as possible.